Stage T1-2 prostate cancer with pretreatment prostate-specific antigen level < or = 10 ng/ml: radiation therapy or surgery?

[1]  H. Levin,et al.  Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. , 1996, Urology.

[2]  J. Blasko,et al.  Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma. , 1995, The Journal of urology.

[3]  A. D'Amico,et al.  A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. , 1995, The Journal of urology.

[4]  R. Abrams,et al.  Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. , 1995, Urology.

[5]  A. Pollack,et al.  Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome. , 1995, Urology.

[6]  K. Wallner,et al.  Significance of normal serum prostate-specific antigen in the follow-up period after definitive radiation therapy for prostatic cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. B. Smith,et al.  The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. , 1994, The Journal of urology.

[8]  A. Zietman,et al.  Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. , 1994, The Journal of urology.

[9]  T. Stamey,et al.  The value of serial prostate specific antigen determinations 5 years after radiotherapy: steeply increasing values characterize 80% of patients. , 1993, The Journal of urology.

[10]  A W Partin,et al.  Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. , 1993, The Urologic clinics of North America.

[11]  A. V. von Eschenbach,et al.  Prostate‐specific antigen. An important marker for prostate cancer treated by external beam radiation therapy , 1993, Cancer.

[12]  P. Schellhammer,et al.  Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of prostate. , 1993, Urology.

[13]  Galina Pizov,et al.  Correlation of pathologic findings with progression after radical retropubic prostatectomy , 1993, Cancer.

[14]  I. Kaplan,et al.  Prostate specific antigen after external beam radiotherapy for prostatic cancer: followup. , 1993, The Journal of urology.

[15]  P. Humphrey,et al.  Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy. , 1993, The Journal of urology.

[16]  E. Messing,et al.  Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  R. B. Smith,et al.  Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer. , 1992, The Journal of urology.

[18]  J. Oesterling,et al.  Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. , 1991, The Journal of urology.

[19]  E. K. Harris,et al.  Survivorship Analysis for Clinical Studies , 1990 .

[20]  W Hinshaw,et al.  Radical surgery versus radiotherapy for adenocarcinoma of the prostate. , 1982, The Journal of urology.

[21]  Kathleen E. Kish,et al.  1 Results of 3d conformal radiotherapy in the treatment of 707 patients with localized prostate cancer , 1995 .

[22]  F. Paul,et al.  Pre-treatment psa as a predictor of long-term outcome in patients definitively irradiated for prostatic carcinoma , 1994 .

[23]  R. Mohan,et al.  Early observations of acute and chronic toxicity & psa response in patients with carcinoma of the prostate treated on a dose escalation study with 3D-CRT , 1994 .

[24]  D. Cox.  Regression Models and Life-Tables , 1972 .